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Abstract
Background—Aromatase inhibitor (AI) therapy results in substantial survival benefits in
hormone receptor-positive breast cancer. Poor adherence and discontinuation rates of AI therapy
are high, primarily due to treatment-related toxicities such as musculoskeletal pain. While pain-
related symptoms may worsen during AI therapy, we hypothesized that non-persistence with AI
therapy was associated with symptoms which were present prior to treatment initiation.
Methods—Postmenopausal women initiating AI therapy who were enrolled in a prospective
clinical trial completed questionnaires at baseline to assess sleep, fatigue, mood, and pain. Reasons
for treatment discontinuation during the first year of treatment were recorded. Associations
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between baseline patient-reported symptoms and treatment discontinuation due to toxicity were
identified using logistic regression.
Results—Four hundred forty-nine patients were evaluable. Odds of treatment discontinuation
were higher in patients who reported a greater number of symptoms prior to AI initiation. Baseline
poor sleep quality was associated with early treatment discontinuation, with an odds ratio (OR) of
1.91 (95% CI 1.26–2.89; p=0.002). Baseline presence of tired feeling and forgetfulness had
similar odds ratios for discontinuation (OR 1.76 (95% CI 1.15–2.67, p=0.009) and OR 1.66 (95%
CI 1.11–2.48, p=0.015), respectively). Increasing total number of baseline symptoms was
associated with increased likelihood of treatment discontinuation, with an OR 1.89 (95% CI 1.20–
2.96; p=0.006) for 3–5 symptoms versus 0–2 symptoms.
Conclusions—Symptom clusters in breast cancer survivors present prior to initiation of
adjuvant AI therapy may negatively impact persistence with therapy. Interventions to manage
these symptoms may improve breast cancer outcomes and quality of life.
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Introduction
Aromatase inhibitors (AI) are routinely used for adjuvant therapy of postmenopausal women
with estrogen receptor (ER)-positive early stage breast cancer. Randomized controlled trials
have demonstrated improvements in disease free (DFS) and overall survival (OS) with AI
therapy compared to tamoxifen.1, 2 Early discontinuation of AI therapy however has been
observed in more than a quarter of patients, primarily due to toxicity of therapy.3, 4 Non-
adherence to AI therapy has been associated with increases in mortality.5
The most common toxicities reported by AI-treated patients are musculoskeletal symptoms,
including arthralgias and myalgias.3 Attempts to identify the cause of these side effects have
focused upon clinical and treatment factors such as time since menopause, body mass index,
prior tamoxifen therapy, and prior taxane chemotherapy.3, 6–8 Despite these studies, the
etiology of AI toxicity remains undefined, although it is believed to be due, at least in part,
to estrogen depletion.9, 10 Vitamin D deficiency may also play a role in the development of
toxicity.11
Studies of breast cancer survivors have demonstrated high rates of patient-reported
symptoms, including pain, insomnia, fatigue, cognitive dysfunction, and mood disorders,
which can be present during all phases of treatment and can persist into the survivorship
period.12, 13 A similar constellation of symptoms is commonly reported by patients with
other chronic pain conditions, including fibromyalgia and temporomandibular joint
disorder.14 In patients with breast cancer, these symptoms may partly arise from the multiple
treatment modalities used for disease management, including surgery, chemotherapy,
radiation therapy, and/or endocrine therapy. In addition, these symptoms may be related to
the stress of the diagnosis itself.15
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Using data from the 503-patient Exemestane and Letrozole Pharmacogenetics (ELPh) Trial,
we previously reported associations between clinical and treatment factors and early
discontinuation of therapy due to toxicity.3 In that study, more than 75% of patients reported
musculoskeletal pain at the time of discontinuation. Based on the literature from other
chronic pain disorders, we hypothesized that some breast cancer patients who develop
musculoskeletal pain might also have other symptoms seen in response to stressors such as
sleep disturbances, fatigue, mood disorders, and cognitive dysfunction.16 If this were the
case, then it is possible that some individuals discontinue AI therapy because of their total
symptom burden at baseline, not solely because of emergence of their musculoskeletal
pain.17, 18 In this manuscript we report associations between the presence of patient-reported
symptoms prior to initiation of an AI and treatment discontinuation within 1 year of starting
the drug in the ELPh Trial.
Methods
Study participants
Post-menopausal women with stage 0-III hormone receptor positive breast cancer who were
initiating treatment with an AI were eligible for enrollment on the ELPh trial
(www.clinicaltrials.gov NCT00228956). Details of the ELPh trial have been reported
elsewhere.19 In brief, all indicated surgery, chemotherapy, and radiation therapy were
completed prior to enrollment, and patients who previously received tamoxifen therapy were
permitted to enroll. The clinical trial was approved by the Institutional Review Boards at all
three participating sites, and patients were required to provide written informed consent
prior to undergoing study-related procedures.
Study procedures
Patients were randomized 1:1 to treatment with exemestane (Aromasin, Pfizer, New York,
USA) 25 milligrams orally daily or letrozole (Femara, Novartis, Basel, Switzerland) 2.5
milligrams orally daily. Prior to AI initiation, enrolled patients completed a battery of
questionnaires and underwent phlebotomy. Patients then initiated treatment, and returned to
the clinic for follow-up assessments, including phlebotomy and questionnaire completion,
after 1, 3, 6, 12, and 24 months of AI therapy.
Questionnaires
At each time point, patients completed the following questionnaires: depression (Center for
Epidemiologic Studies – Depression (CESD)),20 anxiety (Hospital Anxiety and Depression
Scale-Anxiety (HADS-A)),21 sleep quality (Pittsburgh Sleep Quality Index (PSQI)),22 and
general symptoms including joint pain, fatigue, difficulty concentrating, forgetfulness, and
vaginal dryness (the Breast Cancer Prevention Trial (BCPT) symptom checklist).23
Laboratory studies
Serum samples obtained at the baseline and 3 month time points were assayed for estradiol
(E2), estrone-1-sulfate (E1S), and estrone (E1) using an ultrasensitive gas chromatography
tandem mass spectroscopy assay, as previously described.24 The lower limit of
quantification for E2 was 0.625 pg/ml, for E1S was 2.88 pg/ml, and for E1 was 1.56 pg/ml.
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Statistical plan
The primary objective of the ELPh trial was to determine the genetic predictors of change in
breast density after 24 months of either an azole (letrozole) or a steroidal (exemestane) AI
medication; these results are being published separately.25 The primary objective of the
exploratory analysis reported in this manuscript was to investigate associations between
patient-reported symptoms prior to AI initiation and discontinuation of AI therapy due to
toxicity during the initial 12 months of therapy.
Validated questionnaires to evaluate fatigue or cognitive dysfunction were not included in
this trial. Therefore, to investigate these symptoms, the following individual items on the
BCPT questionnaire23 were analyzed: “joint pain” (pain), “forgetfulness” and “difficulty
concentrating” (cognitive dysfunction), and “tired feeling” (fatigue). “Vaginal dryness” was
also analyzed as a common AI-related symptom thought to be predominantly peripherally
rather than centrally mediated. Presence of each symptom was defined as the patient
reporting of any degree of severity of the symptom (i.e., slightly, moderately, quite a bit, or
extremely).
Descriptive analyses were conducted for all baseline characteristics for the entire sample and
by discontinuation status. Odds ratios and their significance comparing characteristics for
those who discontinued AI therapy due to symptoms by the end of one year to those who
remained on treatment at one year were calculated using logistic regression. Baseline
characteristics that were associated with AI discontinuation due to symptoms by the end of
the first year by a p-value <0.20 were included in a multivariable model where a stepwise
procedure was utilized to find the variables significantly associated with AI discontinuation
due to toxicity. Estrogen measurements were natural log transformed in all models.
Additionally, symptoms were combined to account for the total number of symptoms each
patient experienced at baseline. Symptoms included in this variable were sleep quality (poor:
PSQI >5 vs. good: PSQI ≤5), concentration (any severity vs. none or no severity), tired
feeling (any severity vs. none or no severity), anxiety (no: HADS A ≤7 vs. borderline or
definite: HADS A >7), and depression (no: CESD<16 vs. possible or probable: CESD≥16).
If the baseline characteristic score was missing, it was conservatively coded as a 0 and the
total number of symptoms was summed for each patient for a final number of symptoms
ranging from zero to five. The total number of symptoms was dichotomized as being either
0–2 or 3–5 and association between this variable and AI discontinuation was assessed in the
univariate and multivariable setting.
All analyses were performed in SAS v9.3 (SAS Institute, Inc, Cary, NC).
Results
Baseline patient characteristics and treatment discontinuation due to toxicity
The ELPh trial included 503 patients, of whom 500 were randomly assigned to letrozole or
exemestane and treated for 24 months (Figure 1). Enrolled patients who discontinued
therapy within 1 year of treatment initiation because of toxicity were compared to those who
continued study participation beyond the 1 year time point (Table 1). During the 24 month
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study, a total of 51 patients discontinued therapy for reasons other than treatment-emergent
toxicity, including inability to undergo phlebotomy and recovery of ovarian function, as
previously reported.3
Of the 449 patients eligible for the analysis, 140 (31.2%) discontinued AI therapy due to
symptoms by the end of the first year of treatment (Table 1). Patients who discontinued
therapy were significantly younger than those who continued therapy (median age 56 vs. 60;
OR 0.97, 95% CI 0.95–1.00; p=0.035). As previously reported,3 no univariate statistically
significant association (at the p=0.05 level) was identified between treatment discontinuation
and BMI (p=0.76), baseline serum estrogen concentration (p=0.50, 0.18, 0.73 for estradiol,
estrone sulfate and estrone, respectively), race (p=0.33), previous treatment with
chemotherapy (p=0.51), taxane-based chemotherapy (p=0.18), radiation therapy (p=0.51),
prior tamoxifen (p=0.18), or prior hormone replacement therapy (p=0.18). Similarly, there
was no statistically significant association between stage of breast cancer at diagnosis and
likelihood of treatment discontinuation (p=0.99). Treatment with exemestane was
significantly associated with an increased risk of treatment discontinuation compared to
letrozole (OR 1.67; 95% CI (1.12–2.51); p=0.012).
Although half of the analyzed patients started AI therapy within 6 months of undergoing
definitive surgery, the time interval ranged from 0 to 109 months. Time from surgery to the
initiation of AI therapy was not significantly associated with AI discontinuation due to
symptoms. Those who discontinued therapy had a median time since surgery of 8 months
(range 1–108), whereas those who remained on AI therapy beyond 12 months had a median
time since surgery of 6 months (range 0–109, p=0.11).
Patient-reported symptoms prior to AI therapy initiation and treatment discontinuation
In the ELPh trial, 67 (15.0%) patients reported being possibly or probably depressed at the
time of AI initiation (using the CESD), and 64 (14.3%) reported being borderline or
definitely anxious (using HADS-A, Table 1; Figure 2). Analysis of depressive
symptomatology scores as a dichotomous variable (possibly or probably depressed versus
not depressed) using the CESD questionnaire did not demonstrate a statistically significant
association between depression prior to AI initiation and increased risk of treatment
discontinuation within the first year (OR 1.50; 95% CI 0.88–2.58; p=0.14). Similarly, no
significant association was identified between pre-existing anxiety assessed using the
HADS-A questionnaire and discontinuation of AI therapy (OR 1.10; 95% CI 0.62–1.93;
p=0.75).
In the ELPh trial, 206 patients (47.9%) reported poor sleep quality on the PSQI
questionnaire prior to initiation of AI therapy (Table 1; Figure 2). A larger percentage of
patients with poor sleep quality prior to AI initiation discontinued therapy because of
toxicity by 1 year compared to those with good sleep quality (59.0% vs. 42.9%; OR=1.91,
95% CI 1.26–2.89; p=0.002). Of the 206 patients who reported poor sleep quality prior to AI
initiation, 139 (67.5%) reported poor sleep quality at 75% or more of their subsequent visits
during AI therapy and seven discontinued after reporting sleep problems at the initial
assessment. Fifty-seven of these 139 (41.0%) patients discontinued AI treatment by the end
of one year.
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The other patient-reported symptoms were collected using a general symptom questionnaire
(Table 1; Figure 2). No statistically significant association was identified between patient-
reported presence of joint pain at baseline and treatment discontinuation due to toxicity
(63.8% vs 56.2%, OR 1.37, 95% CI 0.91–2.08; p=0.14). Patients who reported forgetfulness
or feeling tired prior to AI initiation were more likely to discontinue therapy due to toxicity
compared to those who did not report having the symptom (forgetfulness: 55.1% vs. 42.5%;
OR 1.66, 95% CI 1.11–2.48; p=0.015; tired feeling: 67.4% vs. 54.1%; OR 1.76, 95% CI
1.15–2.67; p=0.009). In addition, there was no statistically significant univariate association
between presence of difficulty concentrating prior to starting AI therapy and treatment
discontinuation (28.1% vs. 21.2%; OR 1.45, 95% CI 0.92–2.13; p=0.11) or vaginal dryness
and treatment discontinuation (37.0% vs. 29.6%; OR 1.39, 95% CI 0.91–2.13; p=0.13).
The following 5 symptoms were combined to assess if having more symptoms at baseline
was associated with treatment discontinuation: poor sleep quality (PSQI>5), depression
(CESD≥16), anxiety (HADS A≥7), any degree of tired feeling, and any degree of difficulty
concentrating. Patients who reported a greater number of symptoms prior to treatment
initiation were more likely to discontinue therapy because of toxicity (Figure 3). There was a
statistically significant difference in treatment discontinuation rate among those who
reported 0, 1–2, and 3–5 symptoms prior to AI initiation (p=0.006). Of the 117 patients who
did not report any of these symptoms at baseline, 26 (22%) discontinued AI therapy within 1
year because of side effects. Of the 225 patients who reported one or two symptoms before
AI initiation, 69 (31%) discontinued AI therapy. In contrast, of the 107 patients with 3 or
more of these symptoms, 45 (42%) discontinued AI therapy. Compared to those patients
who reported none of the symptoms at baseline, those patients with 1 or 2 symptoms at
baseline had an increased likelihood of AI discontinuation during the first year with an odds
ratio of 1.55 (95% CI 0.92–2.60), and those with 3–5 symptoms had an increased likelihood
with an odds ratio of 2.54 (95% CI 1.42–4.54; p=0.007). Furthermore, we found, on
average, that individuals who discontinued AI therapy within 1 year because of toxicity
reported having 3 or more symptoms at 37% of their subsequent visits, compared with 22%
for who did not discontinue therapy (p=0.0009).
Multivariable analysis of predictors of treatment discontinuation due to toxicity
Multivariable logistic regression was used to evaluate predictors of treatment
discontinuation due to toxicity. Including all variables univariately related to discontinuation
from Table 1 we sought a more parsimonious model using a stepwise approach. Thus we
evaluated a model with age, AI medication, sleep quality and concentration (Table 2). E1S
at baseline (p=0.14) and pain score (p=0.12) were the last variables to be removed from the
model. With all 5 variables included, the area under the curve (measure of predictive power
in logistic regression) was 0.68. In either the full model or the reduced model that excluded
E1S and pain score, both poor sleep quality and difficulty concentrating remained
statistically significant. In the reduced model shown in Table 2, those with poor sleep
quality had 1.79 times the odds of discontinuing AI medication by the end of the first year of
treatment, holding age, AI medication, and concentration severity constant (p=0.01). Those
with moderate to extreme difficulty concentrating had 2.62 times the odds of discontinuing
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treatment, holding all other variables constant (p=0.017). The area under the curve of this
reduced model was 0.65.
A second model was evaluated to specifically analyze the effect of total number of
symptoms at baseline (3–5 vs. 0–2; Table 3). In this model, age (OR 0.97; p=0.03), AI
medication (OR 1.66; p=0.02), and 3 or more symptoms (OR 1.68; p=0.03) were statistically
significantly associated with treatment discontinuation due to toxicity. This model also
included pain score (VAS) where each 1 point increase in pain increased the odds of
discontinuation by 1.09 (p=0.07). This model had an area under the curve of 0.64. When
baseline E1S (p=0.17) was also included in this base model the area under the curve
increased slightly to 0.65.
Discussion
Early discontinuation of AI therapy, which is associated with worse breast cancer outcomes,
is frequently due to the development of side effects, especially musculoskeletal toxicity.3, 5
Numerous prior studies of AI therapy have reported increased risk of developing
musculoskeletal symptoms during AI treatment with factors such as age, body mass index,
pre-existing pain or arthritis, prior chemotherapy, and prior tamoxifen.3, 6–8 For this
analysis, we instead focused on associations between patient-reported non-pain symptoms
present before initiation of AI therapy, such as poor sleep quality, fatigue, depression, and
anxiety, and increased rates of premature treatment discontinuation because of toxicity. In
the relatively large ELPh trial, we found that pre-existing poor sleep quality and difficulty
concentrating were strongly associated with early treatment discontinuation due to toxicity.
In addition, increased symptom burden prior to AI therapy initiation was associated with
both increased symptom burden during AI treatment and increased likelihood of treatment
discontinuation within 1 year.
Our findings are consistent with those reported in the MA.27 trial of exemestane versus
anastrozole.26 In that study, the hazard ratio of early treatment discontinuation due to bother
from side effects from prior treatment that were present at the time of AI initiation was 1.29
(95% CI 1.08–1.55; p=0.006). The contributions of specific side effects were not described.
The symptom cluster of mood disorders, fatigue, and difficulty sleeping is frequently
identified in patients across diseases, including cancer and chronic pain syndromes.27 Many
of the published reports evaluating symptom clusters in breast cancer patients have focused
on patients undergoing therapy with short-term treatment modalities, including
chemotherapy and/or radiation therapy. For example, in one study patients who reported a
greater number of symptoms prior to the start of chemotherapy were more likely to report
worse symptoms during the treatment.27 Other studies have identified specific patterns of
change in symptoms over time during chemotherapy and radiation. These patterns ultimately
impact functional status and quality of life and may influence patient management.17, 28 In
contrast, few published reports have focused on patterns of specific symptoms that occur
during long-term adjuvant endocrine therapy. Analogous to what has previously been seen
with chemotherapy, in the ELPh trial we identified an association between greater number
of symptoms prior to treatment and decreased persistence with AI therapy due to toxicity.
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The symptoms of poor sleep and difficulty concentrating stood out as clinically important
contributors to this symptom cluster.
Knowledge of these associations is clinically relevant, since these symptoms are not
frequently recognized as problematic and are not typically carefully assessed or aggressively
managed by oncologists. Indeed, since difficulty sleeping and complaints of fatigue are
common in patients with breast cancer29 and are often thought to be self-limited side effects
of prior therapies including chemotherapy and radiation therapy, oncologists may not
appreciate that the presence of these symptoms may compromise future treatments. These
results raise the possibility that asking patients about these symptoms and addressing them at
the time of AI initiation, or even prophylactically, could identify patients at risk, and allow
the implementation of measures to improve adherence/persistence with subsequent adjuvant
endocrine therapy.
Although management of these symptoms is essential for improving quality of life, these
data suggest that it may also impact breast cancer outcomes if improvement in symptoms led
to increased adherence to and persistence with therapy. There is a paucity of effective
treatment options for poor sleep, cognitive problems, and fatigue in cancer survivors.
Numerous clinical trials have been conducted to test various pharmacologic therapies for
fatigue, although few studies of pharmacologic treatments have been conducted specifically
for sleep disturbance in cancer patients.18 Meta-analyses have demonstrated a statistically
significant benefit from methylphenidate compared to placebo for cancer-related fatigue,
although the clinical benefit is modest.30 There are also considerable data to support use of
cognitive behavioral therapy (CBT) for treatment of both insomnia and fatigue in cancer
patients.30–32 Use of CBT is recommended in the National Comprehensive Cancer Network
(NCCN) guidelines for management of Cancer-Related Fatigue,33 although it is unknown
how often these behavioral techniques are actually used in clinical practice. Improvements
in fatigue have also been noted in cancer patients treated with other non-pharmacologic
interventions, including physical activity.30 Although a number of treatment options are
listed in the currently available national guidelines, no individual modality is preferred.33
Our study has multiple strengths. The findings were derived from a large, prospective
clinical trial in which reasons for discontinuation were prospectively recorded. Validated
questionnaires were used to assess patient-reported sleep, pain, and mood disorders,
although fatigue and cognitive function data elements had to be obtained from a more
general symptom questionnaire. The study medication was provided to the patients by the
study, so cost of the medication was not a factor in persistence with therapy.
In this analysis we identified a numerically greater but not statistically significant increased
risk of treatment discontinuation within 1 year in patients treated with a taxane-based
chemotherapy regimen, which we and others have previously reported. One important
difference between the prior analysis of the ELPh trial and this one is the focus on
discontinuation specifically within the first year of AI therapy. This 1 year limitation was
intended to restrict analysis to symptoms likely due to the AI medication, and less likely to
changes that can occur over time with the natural aging process, such as worsening
osteoarthritis. Our findings suggest that pre-existing symptoms are more strongly associated
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with AI discontinuation due to toxicity than clinical factors such as prior treatment with
chemotherapy. However, it remains possible that prior treatments such as chemotherapy
contributed to the symptoms reported by patients at the time of the baseline study visit.
Our findings demonstrate the importance of symptom clusters that include poor sleep and
difficulty concentrating in patients with breast cancer, and the potential detrimental effects
of these symptoms not just on quality of life but also on AI treatment adherence and breast
cancer outcomes. Therapies to improve the constellation of symptoms rather than those that
target individual symptoms should be considered to allow optimal patient care. Clinical
trials are warranted to evaluate the impact of management of symptom clusters on adherence
to potentially life-saving adjuvant endocrine therapies.
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Figure 1. Consort diagram of patient flow in the ELPh trial
D/c = discontinued
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Figure 2. Percentage of evaluable patients who continued or discontinued aromatase inhibitor
(AI) therapy within the first year of treatment by baseline symptoms present before AI initiation
Dotted bars represent the percentage of total evaluable patients who discontinued AI therapy
within 1 year, and solid bars represent the percentage of total evaluable patients who
continued AI therapy beyond 1 year. Odds ratios (OR) and p values are given for those
comparisons that were statistically significant. Conc = concentrating.
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Figure 3. Percentage of patients who discontinued aromatase inhibitor (AI) therapy according to
the number of symptoms present prior to AI initiation
The number of patients in each group is given below the x axis. OR: odds ratio.
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Table 2
Multivariable logistic regression analysis of predictors of AI treatment discontinuation,
including individual symptoms
Multivariable logistic regression resulting from step-down analysis of treatment discontinuation during the
first year of AI therapy due to baseline sleep and concentration difficulties before AI initiation and patient
characteristics (n=428, area under the curve = 0.65)
Variable Odds Ratio (95% CI) p-value
Age 0.97 (0.95–1.00) 0.028
Drug (exemestane vs. letrozole) 1.63 (1.07–2.49) 0.024
Sleep quality (PSQI >5 vs. ≤5) 1.79 (1.15–2.79) 0.010
Concentration (vs. none) 0.017
 Not at all or slight 0.75 (0.42–1.33)
 Moderate-extreme 2.62 (1.22–5.65)
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Table 3
Multivariable logistic regression analysis of predictors of AI treatment discontinuation
including symptom clusters
Multivariable logistic regression resulting from step-down analysis of treatment discontinuation during the
first year of AI therapy due to number of symptoms present before AI initiation and patient characteristics
(n=447, area under the curve = 0.64)
Variable Odds Ratio (95% CI) p-value
Age 0.97 (0.95–1.00) 0.025
Drug (exemestane vs. letrozole) 1.66 (1.10–2.50) 0.016
VAS 1.09 (0.99–1.20) 0.067
Total Number of Symptoms (vs. 2 or less)
 3 or more 1.68 (1.05–2.70) 0.031
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